AVERI Drug Patent Profile
✉ Email this page to a colleague
When do Averi patents expire, and what generic alternatives are available?
Averi is a drug marketed by Avion Pharms and is included in one NDA.
The generic ingredient in AVERI is desogestrel; ethinyl estradiol. There is one drug master file entry for this compound. Fifteen suppliers are listed for this compound. Additional details are available on the desogestrel; ethinyl estradiol profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Averi
A generic version of AVERI was approved as desogestrel; ethinyl estradiol by DURAMED PHARMS BARR on August 12th, 1999.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for AVERI?
- What are the global sales for AVERI?
- What is Average Wholesale Price for AVERI?
Summary for AVERI
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| DailyMed Link: | AVERI at DailyMed |
US Patents and Regulatory Information for AVERI
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Avion Pharms | AVERI | desogestrel; ethinyl estradiol | TABLET;ORAL-21 | 218933-001 | May 2, 2025 | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| Avion Pharms | AVERI | desogestrel; ethinyl estradiol | TABLET;ORAL-28 | 218933-002 | May 2, 2025 | AB | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
